Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RGN-457
- Development stage
- Preclinical
- Lead developer
- RegeneRx Biopharmaceuticals
- Modality
- Peptides
- Administration
- Inhalation
01
Overview
RGN-457 is an inhaled peptide biologic formulation of thymosin beta 4 (Tβ4), a naturally occurring 43-amino acid peptide, developed by RegeneRx Biopharmaceuticals. It is designed for the treatment of cystic fibrosis (CF) and other pulmonary indications. The drug works by reducing the cohesivity and viscosity of CF sputum, which is often thickened by high concentrations of extracellular actin, thereby facilitating airway clearance. Additionally, RGN-457 exhibits anti-inflammatory properties that may help mitigate lung damage. RegeneRx holds the development rights under an exclusive worldwide license from the National Institutes of Health (NIH). As of 2008, the company had completed preclinical work necessary for an IND application and was seeking a strategic partner for further clinical development.
- Other names
- thymosin beta 4Tβ4
02
Targets
Actin filament proteinsPlectin–actin complex
Beyond the preview
Go deeper on RGN-457.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RGN-457.